784 related articles for article (PubMed ID: 28756138)
1. Mutant p53 as a target for cancer treatment.
Duffy MJ; Synnott NC; Crown J
Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
Duffy MJ; Synnott NC; Crown J
Breast Cancer Res Treat; 2018 Jul; 170(2):213-219. PubMed ID: 29564741
[TBL] [Abstract][Full Text] [Related]
3. p53 as a target for the treatment of cancer.
Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
[TBL] [Abstract][Full Text] [Related]
4. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
[TBL] [Abstract][Full Text] [Related]
5. Targeting p53 for the treatment of cancer.
Duffy MJ; Synnott NC; O'Grady S; Crown J
Semin Cancer Biol; 2022 Feb; 79():58-67. PubMed ID: 32741700
[TBL] [Abstract][Full Text] [Related]
6. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
7. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
[TBL] [Abstract][Full Text] [Related]
8. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
10. Prima-1 and APR-246 in Cancer Therapy.
Zatloukalová P; Galoczová M; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
[TBL] [Abstract][Full Text] [Related]
12. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.
Aryee DN; Niedan S; Ban J; Schwentner R; Muehlbacher K; Kauer M; Kofler R; Kovar H
Br J Cancer; 2013 Nov; 109(10):2696-704. PubMed ID: 24129240
[TBL] [Abstract][Full Text] [Related]
13. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.
Bauer MR; Joerger AC; Fersht AR
Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5271-80. PubMed ID: 27551077
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Wiman KG
Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
[TBL] [Abstract][Full Text] [Related]
15. Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies.
Kaur RP; Vasudeva K; Kumar R; Munshi A
Curr Pharm Des; 2018; 24(30):3566-3575. PubMed ID: 30255744
[TBL] [Abstract][Full Text] [Related]
16. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
17. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.
Michaeli O; Luz I; Vatarescu M; Manko T; Weizman N; Korotinsky Y; Tsitrina A; Braiman A; Arazi L; Cooks T
Cell Death Dis; 2024 Jun; 15(6):426. PubMed ID: 38890278
[TBL] [Abstract][Full Text] [Related]
18. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.
Bao W; Chen M; Zhao X; Kumar R; Spinnler C; Thullberg M; Issaeva N; Selivanova G; Strömblad S
Cell Cycle; 2011 Jan; 10(2):301-7. PubMed ID: 21239882
[TBL] [Abstract][Full Text] [Related]
19. A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.
Ceder S; Eriksson SE; Cheteh EH; Dawar S; Corrales Benitez M; Bykov VJN; Fujihara KM; Grandin M; Li X; Ramm S; Behrenbruch C; Simpson KJ; Hollande F; Abrahmsen L; Clemons NJ; Wiman KG
EMBO Mol Med; 2021 Feb; 13(2):e10852. PubMed ID: 33314700
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological reactivation of p53 as a strategy to treat cancer.
Zawacka-Pankau J; Selivanova G
J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
